DrugDev will present an educational webinar, “Silent Partners? How Virtual Clinical Trials Impact Sites” on February 12, featuring expert speaker Nathan Morton, Director and Co-Owner of Coastal Carolina Research Center. The complimentary live webinar will explore how technology and virtual clinical trials are rapidly changing the landscape for investigators.

Webinar: Silent Partners? – How Virtual Clinical Trials Impact Sites
Guest Speaker: Nathan Morton, Director and Co-Owner, Coastal Carolina Research Center
Date: February 12, 2015
Time: 10:00-11:00am EST
CLICK TO REGISTER
This webinar is complimentary

The webinar will feature case studies that highlight the changes and challenges for sites, best practices for adapting to changes, and an interactive Q&A session. Topics will include:

  • How technology and innovation within the clinical trial process are rapidly changing the landscape for investigators and their day to day operations.
  • What it takes to adapt and survive in this world of virtual clinical trials
  • How sponsors and CROs can partner with sites to take them along on their technological journey

As the Director and Co-Owner of Coastal Carolina Research Center, Nathan Morton provides strategic planning and operational oversight for a dedicated research center and a clinical staff of 22. The center has managed over 350 Phase I-IV clinical trials in multiple therapeutic areas including vaccines, CNS, Pain, Psychiatric, Cardiovascular, Dermatology, and Gastroenterology.

About DrugDev
DrugDev provides technology-enabled solutions to help sponsors, CROs and sites do more trials together. Built around the industry’s largest network of global investigators actively seeking new trial opportunities, DrugDev offers a unified suite of cloud-based tools and expert professional services for site selection and startup, global investigator payments, and clinical trial optimization. DrugDev is also the trusted third-party host of the Investigator Databank, a revolutionary global collaboration which enables Janssen, Lilly, Merck, Pfizer and Novartis to improve site selection and reduce administrative burden by sharing site information with each other and with 200,000 investigators worldwide. Learn how DrugDev can help you do more trials at www.drugdev.com.